NCT01764295 is a Phase 3 clinical trial of DWJ1276 in Hypertension, sponsored by Daewoong Pharmaceutical Co. LTD..

Who is sponsoring NCT01764295?

NCT01764295 is sponsored by Daewoong Pharmaceutical Co. LTD..

What drugs are being tested in NCT01764295?

Interventions in NCT01764295: DWJ1276, Olmesartan, Rosuvastatin, Placebo.

What condition does NCT01764295 study?

NCT01764295 studies Hypertension, Dyslipidemia.

Is NCT01764295 still recruiting?

NCT01764295 is currently completed. Last updated 22 August 2013.

Last reviewed 2013-08-22 · How we verify

NCT01764295

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-institutional, Randomized, Double-Blind, Placebo-Control, Factorial Design, 4-arms, 8 Week Administration, Phase 3 Clinical Study for Patients With Hypertension Associated With Dyslipidemia

Completed Phase 3 Last updated 22 August 2013

What this trial tests

Phase 3 trial testing DWJ1276 in Hypertension in 150 participants. Completed in 1 July 2013.

Timeline

1 September 2012

Primary endpoint
1 May 2013

1 July 2013

Quick facts

Lead sponsor	Daewoong Pharmaceutical Co. LTD.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	triple
Primary purpose	treatment
Enrollment	150
Start date	1 September 2012
Primary completion	1 May 2013
Estimated completion	1 July 2013
Sites	1 location across South Korea

Drugs / interventions tested

DWJ1276 — full drug profile →
Olmesartan (OLMESARTAN) — full drug profile →
Rosuvastatin (rosuvastatin) — full drug profile →
Placebo

Conditions studied

Hypertension — all drugs for Hypertension →
Dyslipidemia — all drugs for Dyslipidemia →

Sponsor

Daewoong Pharmaceutical Co. LTD. — full company profile →

Who can join

Adults 20 to 80, any sex, with Hypertension or Dyslipidemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

LDL-C percent change of DWJ1276 from baseline
Time frame: 8weeks
DBP change of DWJ1276 from baseline
Time frame: 8weeks

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of DWJ1276

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.
Bahiru E, de Cates AN, Farr MR, Jarvis MC, et al · · 2017 · cited 59× · PMID 28263370 · DOI 10.1002/14651858.cd009868.pub3
Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin
Park JS, Shin JH, Hong TJ, Seo HS, et al · · 2016 · cited 23× · PMID 27574399 · DOI 10.2147/dddt.s112873

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Daewoong Pharmaceutical Co. LTD. trials

Trials by the same sponsor.

NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01764295 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
Last refreshed: 22 August 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01764295.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing